Treatment with interleukin-33 is non-toxic and protects retinal pigment epithelium in an ageing model of outer retinal degeneration

Alison J Clare*, David A Copland, Lindsay B Nicholson, Jian Liu, Chris R Neal, Stephen Moss, Andrew D Dick, Sofia Theodoropoulou

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)

16 Downloads (Pure)

Abstract

The leading cause of central vision loss, age-related macular degeneration (AMD), is a degenerative disorder characterized by atrophy of retinal pigment epithelium (RPE) and photoreceptors. For 15% of cases, neovascularization occurs, leading to acute vision loss if left untreated. For the remaining patients, there are currently no treatment options and preventing progressive RPE atrophy remains the main therapeutic goal. Previously, we have shown treatment with interleukin-33 can reduce choroidal neovascularization and attenuate tissue remodelling. Here, we investigate IL-33 delivery in aged, high-fat diet (HFD) fed mice on a wildtype and complement factor H heterozygous knockout background. We characterize the non-toxic effect following intravitreal injection of IL-33 and further demonstrate protective effects against RPE cell death with evidence of maintaining metabolic retinal homeostasis of Cfh+/-~HFD mice. Our results further support the potential utility of IL-33 to prevent AMD progression.

Original languageEnglish
Number of pages5
JournalJournal of Cellular and Molecular Medicine
Early online date20 Oct 2020
DOIs
Publication statusE-pub ahead of print - 20 Oct 2020

Keywords

  • age‐related macular degeneration
  • complement factor H
  • IL‐33
  • retinal pigment epithelium

Fingerprint Dive into the research topics of 'Treatment with interleukin-33 is non-toxic and protects retinal pigment epithelium in an ageing model of outer retinal degeneration'. Together they form a unique fingerprint.

Cite this